Kazia Therapeutics Limited KZIA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
26/100
Developing

Ranked against 712 peers in Biotechnology

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous … Full KZIA analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 94.4th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.00), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.05), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
23
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where KZIA ranks in Biotechnology

Kazia Therapeutics Limited ranks #556 of 713 scored companies in Biotechnology by moat score — the top 78%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
552 Addex Therapeutics Ltd ADXN 27/100 Developing
553 Actinium Pharmaceuticals, Inc. ATNM 26/100 Developing
554 Cidara Therapeutics, Inc. CDTX 26/100 Developing
555 Spyre Therapeutics, Inc. SYRE 26/100 Developing
556 Kazia Therapeutics Limited KZIA 26/100 Developing
557 Zenas BioPharma, Inc. ZBIO 26/100 Developing
558 BioRestorative Therapies, Inc. BRTX 26/100 Developing
559 VistaGen Therapeutics, Inc. VTGN 26/100 Developing
560 Artiva Biotherapeutics, Inc. ARTV 26/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How KZIA scores on the Corporate Default defenses

Pricing Power

Score 23 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 7 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 6 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 68 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 6 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 35 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding KZIA's moat

What is Kazia Therapeutics Limited's moat score?

Kazia Therapeutics Limited (KZIA) scores 26 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #556 of 713 scored companies in Biotechnology, the top 78%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (68/100) and its weakest is Customer Stickiness (6/100).

How does Kazia Therapeutics Limited compare with other Biotechnology companies?

Kazia Therapeutics Limited ranks #556 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Spyre Therapeutics, Inc. (SYRE) at 26 just above it and Zenas BioPharma, Inc. (ZBIO) at 26 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Kazia Therapeutics Limited scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Kazia Therapeutics Limited?

The Corporate Default template measures 6 defenses, and KZIA scores: Pricing Power (23), Cost Advantage (7), Customer Stickiness (6), Capital Efficiency (68), Resilience (6), Scale & Market Position (35). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000